OU Portal
  • Log In
  • Welcome
  • Applicants
Z6_60GI02O0O8IDC0QEJUJ26TJDI4
{}
Zavřít
Publikační činnost


preloading...   Probíhá načítání, čekejte prosím...
publicationId :
tempRecordId :
actionDispatchIndex :
navigationBranch :
pageMode :
tabSelected :
isRivValid :
Typ záznamu * : stať ve sborníku (D)
Domácí pracoviště * : Katedra interních oborů (11300)
Název * : Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: A Analysis from Registry of Monoclonal Gammopathies (RMG)
Citace : Hájek, R. Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: A Analysis from Registry of Monoclonal Gammopathies (RMG). In: 60th Annual Meeting of the American-Society-of-Hematology (ASH): Supplement: 1 Meeting Abstract: 2019 2018 San Diego. WASHINGTON, DC 20036 USA: AMER SOC HEMATOLOGY, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, 2018. ISSN 0006-4971.
Podnázev :
Rok * : 2018
Obor * : Onkologie a hematologie
Počet stran * : 1
Strana od * : neuvedeno
Strana do * : neuvedeno
Forma vydání * : Tištená verze
Kód ISBN * : neuvedeno
Kód ISSN : 0006-4971
Název sborníku * : Supplement: 1 Meeting Abstract: 2019
Sborník : Mezinárodní
Název nakladatele * : AMER SOC HEMATOLOGY, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
Místo vydání * : WASHINGTON, DC 20036 USA
Stát vydání : Sborník vydaný v zahraničí
Název konference : 60th Annual Meeting of the American-Society-of-Hematology (ASH)
Místo konání konference * : San Diego
Datum zahájení konference * :
Typ akce podle státní
příslušnosti účastníků akce * :
Celosvětová akce
Kód UT WoS : 000454837606018
EID :
Klíčová slova anglicky * :
Monoclonal Gammopathies (RMG)
Popis v původním jazyce * :
Introduction: Multiple myeloma patients over the age of 65 represent the majority of myeloma population. The main goal was to evaluate treatment outcomes in terms of overall survival for elderly patients based on initial choice of anti-myeloma drugs, and to find potential factors affecting survival. Patients and Methods: This is a retrospective registry based analysis from the Registry of monoclonal gammopathies of the Czech Myeloma Group. Patients with multiple myeloma diagnosed between 2007-2016 over the age of 65 with symptomatic myeloma were included in the analysis. Basic demographic data and disease characteristics were obtained. The Kaplan-Meier estimates were completed by the Greenwood confidence interval. The log-rank test was used to estimate the statistical significance of the difference between the curves. The Cox proportional hazards model was performed to explore the univariate significance of risk factors. Results: Data from 1410 MM patients were obtained. Gender [HR 1.316 (1.124-1.541), p=0.001], age [above 75 vs. 66-75, HR 1.437 (1.221-1.692), p< 0.001], creatinine levels [at cutoff 152 µmol/L, HR 1.613 (1.365-1.905), p< 0.001] and ECOG performance status [0-1 vs. 2-4, 1.869 (1.594-2.191), p< 0.001] were found to significantly affect overall survival. Moreover these risk factors have cumulative effect on overall survival of the patients. Overall survival of patients regardless to above mentioned risk factors treated with upfront bortezomib (N = 880) was median OS 40.4 months (CI: 36.1-44.7), patients treated with upfront thalidomide (N = 370) had median OS 48.1 months (CI: 41.0-55.2), for lenalidomide (N = 64) median overall survival was 53.2 months (CI: 44.6-61.8) and for combination of bortezomib and thalidomide (N = 46) 32.2 months (CI: 26.6-37.8). When any of these risk factors was present the OS in each group shortened. In the group of patients with no risk factors (N = 255) the median OS for bortezomib (N = 126) was not reached,
Popis v anglickém jazyce * :
Typ zdroje financování výsledku * : Jiné veřejné zdroje
Seznam projektů :
ID Projektu Název projektu
Seznam ohlasů : 
Ohlas
R01: RIV/61988987:17110/18:A20020PH

© 2019 Centre for Information Technology

  • Technická podpora :
  • Mgr. Olga Blahutová (phone: +420 597 091 129, phone flap for UO: 1129)
Complementary Content
  • ${title}${badge}
${loading}